HISOAR stated in the latest disclosed investor relations activity record that in terms of raw materials, the price of penicillin products has been continuously declining and hitting new lows in recent years, but there was some recovery in the second quarter of this year, showing a trend of stabilization and rebound; the company maintains communication with global customers and suppliers and has learned that the market holds an overall optimistic attitude towards the price recovery of penicillin products. Whether the price of penicillin products can continue to recover remains to be further observed. The company has laid out multiple fields in raw materials, including anti-infection, hypoglycemic, dermatology, ophthalmology medications, and psychiatric drugs, with related products currently in various stages of research and development such as small-scale trials, pilot tests, and validation. Continuous approvals in the future will expand the company's development space